Cancer Letters
Volume 205, Issue 2 , Pages 207-214 , 18 March 2004

Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma

Received 28 July 2003 ,Revised 24 September 2003 ,Accepted 2 October 2003.

References 

  1. Leuchanteur C, Moutschen M, Princen F, Lopez M, Franzen E, Gielen J, et al.  Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells. Cancer Gene Ther. 2000;7:676–682
  2. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-12, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 2000;165:1847–1853
  3. Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, et al.  Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J. Biol. Regul. Homeost. Agents. 2000;14:275–277
  4. Kohno K, Kurimoto M. Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin. Immunol. Immunopathol. 1998;86:11–15
  5. Kito T, Kuroda E, Yokota A, Yamashita U. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-γ-regulated nitric oxide. J. Neurosurg. 2003;98:385–392
  6. van Sandick JW, Gisbertz SS, ten Berge IJ, Boermeester MA, van der Pouw Kraan TC, Out TA, et al.  Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer. Ann. Surg. 2003;237:35–43
  7. Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT, et al.  Interleukin-18 (IL-18) synergizes with IL-12 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res. 2001;61:884–888
  8. Kim SH, Azam T, Yoon DY, Reznikov LL, Novick D, Rubinstein M, et al. Site-specific mutations in the mature form of human IL18 with enhanced biological activity and decreased neutralization by IL18 binding protein. Proc. Natl Acad. Sci. USA. 2001;98:3304–3309
  9. Paulukat J, Bosmann M, Nold M, Garkisch S, Kampfer H, Frank S, et al.  Expression and release of IL-18 binding protein in response to IFN-γ. J. Immunol. 2001;157:7038–7043
  10. Pages F, Berger A, Lebel-Binay S, Zinzindohoue F, Danel C, Piqueras B, et al.  Proinflamatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol. Lett. 2000;75:9–14
  11. Furuya D, Yagihashi A, Komatsu M, Tsuji N, Kobayashi D, Watanabe N. Serum interleukin-18 concentrations in patients with inflammatory disease. J. Immunother. 2002;25:65–67
  12. Sablotzki A, Friedrich I, Muhling J, Dehne MG, Spillner J, Silber RE, et al. The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion. 2002;17:103–109
  13. Takada H, Ohga S, Mizuno Y, Suminoe A, Matsuzaki A, Ihara K, et al.  Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br. J. Haematol. 1999;106:182–189
  14. Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K, et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogenic bone marrow transplantation. Br. J. Haematol. 2000;109:652–657
  15. Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, et al.  Protective immunity is induced in murine colon carcinoma cells by expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther. 2000;7:247–254
  16. Tanaka F, Hashimoto W, Okamura H, Paul DR, Michael TL, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res. 2000;60:4838–4844
  17. Sugawara I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect. 2000;2:1257–1263
  18. Hegardt P, Widegren B, Li L, Sjogren B, Kjellman C, Sur I, et al. Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol. Immunother. 2001;50:491–501
  19. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, et al.  Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int. J. Cancer (Pred. Oncol.). 1999;84:326–330
  20. Liu L, Sakaguchi T, Kanda T, Hitomi J, Tabata Y, Hatakeyama K. Delivery of interleukin-12 in gelatin hydrogels effectively suppresses development of transplanted colonal carcinoma in mice. Cancer Chemother. Pharmacol. 2003;51:53–57
  21. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, et al.  Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int. J. Cancer. 1999;84:326–330
  22. Hegardt P, Widegren B, Li L, Sjogren B, Kjellman C, Sur I, et al. Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying intrahepatic colon carcinoma. Cancer Immunol. Immunother. 2001;50:491–501
  23. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, et al.  Preoperative serum interleukin-18 levels as a postoperative prognostic marker in patients with gastric carcinoma. Cancer. 2001;92:2050–2055
  24. Nagi H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S. Antitumor effects in mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest. 2000;18:206–213
  25. Yoshimoto T, Tominaga K, Hoshino K, Okamura H, Akira S, Kinukawa N, et al.  IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl Acad. Sci. USA. 1999;96:13962–13966
  26. Takahashi A, Kono K, Ichihara F, Sugai H, Amemiya H, Iizuka H, et al.  Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer. Int. J. Cancer. 2003;104:393–399
  27. Merendino RA, Gangemi S, Ruello A, Bene A, Losi E, Lonbardo G, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int. J. Biol. Markers. 2001;16:126–129
  28. Nakata A, Tsujimura T, Sugihara A, Okamura H, Iwasaki T, Shinkai K, et al.  Inhibition by interleukin18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res. 1999;19:4131–4138
  29. Kikuchi T, Akasaki Y, Joki T, Abe T, Kurimoto M, Ohno T. Antitumor activity of interleukin-18 on mouse glioma cells. J. Immunother. 2000;23:184–189
  30. Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, et al.  Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 genes combined with interleukin-18 administration. Cancer Gene Ther. 2000;7:83–90
  31. Thalmann GN, Sermier A, Rentsuch C, Mohrle K, Cecchin MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J. Urol. 2000;164:2129–2133
  32. Kishida T, Asada H, Satoh E, Tanaka S, Shinya M, Hirai H, et al.  In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 2001;8:1234–1240
  33. Park H, Byun D, Kim TS, Kim YI, Kang JS, Hahm ES, et al.  Enhanced IL-18 expression in common skin tumors. Immunol. Lett. 2001;79:215–219
  34. Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 2002;62:7254–7263
  35. Hashimoto W, Tanaka F, Robbins PD, Taniguchi M, Okamura H, Lotze MT, et al. Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18. Int. J. Cancer. 2003;103:508–513
  36. Nakajima M, Kuwano H, Miyazaki T, Masuda N, Kato H. Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett. 2002;178:99–106

PII: S0304-3835(03)00677-3

doi: 10.1016/j.canlet.2003.10.010

Cancer Letters
Volume 205, Issue 2 , Pages 207-214 , 18 March 2004

Article Tools

* Image Usage & Resolution